Jubilant Pharmova Limited announced that the United States Food and Drug Administration (USFDA) completed its Post-marketing Adverse Drug Experience (PADE) inspection of Jubilant Cadista Pharmaceuticals Inc., USA, on September 19, 2025. The inspection concluded with zero observations, reaffirming Jubilant’s commitment to quality, safety, and compliance. This positive outcome underscores the company’s adherence to stringent regulatory standards.
USFDA Inspection Completion
Jubilant Pharmova Limited announced the successful completion of the United States Food and Drug Administration (USFDA) Post-marketing Adverse Drug Experience (PADE) inspection. The inspection was conducted at Jubilant Cadista Pharmaceuticals Inc., USA, a subsidiary of Jubilant Pharma Limited.
Key Highlights
The inspection, which concluded on September 19, 2025, resulted in zero observations. This outcome highlights Jubilant Pharmova’s dedication to maintaining the highest standards of quality, safety, and compliance in its pharmaceutical operations. The successful completion of the inspection reinforces the company’s commitment to regulatory excellence. The initial announcement was made on September 20, 2025.
About Jubilant Pharma Limited
Jubilant Pharma Limited (JPL), a subsidiary of Jubilant Pharmova, is an integrated global pharmaceutical company. It focuses on manufacturing and supplying Radiopharmaceuticals, Allergy Immunotherapy, and Contract Manufacturing of Sterile Injectables and Non-sterile products. The company operates multiple manufacturing facilities catering to regulated markets, including the USA and Europe.
About Jubilant Pharmova Limited
Jubilant Pharmova Limited is a company with a global presence involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics, and Proprietary Novel Drugs businesses. With facilities catering to regulated markets, the company emphasizes its role as a ‘Partner of Choice’.
Source: BSE
